

On August 1, 2013, the U.S. Food and Drug Administration expanded the indication for Menveo, a meningococcal conjugate vaccine, for use in infants beginning at 2 months of age.

The [National Meningitis Association](#) (NMA) welcomes this additional prevention option to help protect our youngest children from meningococcal disease. As an organization formed by families who have been permanently affected by the disease, we know firsthand how important it is to provide protection to this very vulnerable population.

NMA believes that every parent should understand the potential impact of meningococcal disease and be knowledgeable about vaccination options for their infant children so they can make informed prevention decisions. For more information about the impact of meningococcal disease, we encourage you to watch or read stories from our Moms on Meningitis (M.O.M.s):

- [Clare and Phoenix](#)
- [Echo and Gavin](#)

Meningococcal disease can come on quickly and can lead to death or disability within hours. It is also important for parents and healthcare professionals to be aware of [the symptoms of meningococcal disease](#) in infants so they can better recognize the disease.

We look forward to the day when vaccines are available and used to provide the broadest protection possible against all strains of the disease.